Developer docs
API playgroundTry for free, no card

Search company profiles

Happy Lungs Project

Full company profile

uuid002f5ni

Namestring
Happy Lungs Project
Legal namestring
Happy Lungs Project
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lung cancer advocacy, cancer research funding, patient education resources, clinical trial matching, patient registry programs
Industry2 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services8132
  • Religious, Grantmaking, Civic, Professional, and Similar Organizations813
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Health Services8000
Product category
Patient Advocacy & Cancer Research Non-Profit
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1General Contributions (Donations)
TypeGrants Donations
Description

The primary revenue source is donations and general contributions from individuals, families, and supporters. Operating revenue for 2025 was $307,543 (all general contributions, no grants). For 2024, revenue was $554,878; 2023 was $362,802; 2022 was $922,265 (including $50,000 in grants); 2021 was $216,750.

happylungsproject.org
2Research Grant Funding Facilitation
TypeProfessional Services
Description

The organization facilitates additional research funding by working with cancer research institutions to assist them in securing grant funding for RET-positive research. Since inception in 2021, HLP has awarded more than $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.

happylungsproject.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Programs (research grants and patient services), Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Happy Lungs Project is a 501(c)(3) nonprofit patient advocacy organization that funds and facilitates scientific research into RET-positive lung cancer, operates patient registries (RETgistry, Lung Cancer Genetics Study), and provides patient education, clinical trial matching, and community resources for RET-positive lung cancer patients, caregivers, and the broader scientific community. Since 2021 it has awarded over $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • $1 million+ awarded in RET-positive cancer research grants since 2021
+3 more records
Product overview1 text field

The Happy Lungs Project is a nonprofit organization operating as a patient advocacy and research funding platform rather than a commercial product company. The organization offers a unified suite of patient-focused services including: a RET research funding program (having awarded over $1 million since 2021), a clinical trial matching service, patient registry enrollment support (connecting to RETgistry, GO2, and 23andMe), comprehensive patient education resources, a Video Q&A Series featuring expert scientific advisors, a newsletter program, patient Stories of Hope testimonials, an Expert Q&A service, NCCN guidelines information, and biomarker testing guidance. These services work together to advance RET-positive lung cancer research and empower patients through education and access to clinical trials and registries.

Product and service7 records
1RET Research Funding Program
CategoryResearch Grants
2Clinical Trial Matching Service
CategoryPatient Navigation
3Patient Registry Enrollment Program
CategoryResearch Participation
4Video Q&A Series
CategoryPatient Education
5RET Newsletter Program
CategoryPatient Education
6Stories of Hope Program
CategoryCommunity Support
7Expert Q&A Service
CategoryPatient Education
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lilly is the manufacturer of selpercatinib (Retevmo), one of the two FDA-approved RET inhibitors. Happy Lungs Project collaborates with Lilly on clinical trial awareness, patient education about RET inhibitors, and research updates. Lilly pharmaceutical logo appears in the collaborating organizations section of the HLP website.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MD Anderson is a primary research partner. HLP funds research at MD Anderson including work led by Dr. John Heymach (Chair of Thoracic/Head and Neck Medical Oncology) on RET inhibitor resistance and novel therapies, and Dr. Alexandre Reuben on T-cell immunotherapy approaches. MD Anderson serves as a lead institution in the national RET Research Coordination Center.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

LUNGevity is a leading lung cancer nonprofit. The two organizations collaborate on patient education, research advocacy, and community support for the RET-positive lung cancer community.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CPRIT is a state-funded cancer research institute in Texas. HLP collaborates with CPRIT-funded researchers and institutions working on RET-positive lung cancer research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UT Southwestern is a research partner where HLP-funded research is conducted, including work by Ralf Kittler on characterizing RET fusions and resistance mechanisms. UT Southwestern is also a partner in the national RET Research Coordination Center.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MGH is a primary research partner. HLP funds research at MGH including the RETgistry global registry (led by Dr. Jessica Lin), novel immunotherapeutic approaches (led by Dr. Justin Gainor), and work on resistance mechanisms. MGH is a core research institution for RET-positive lung cancer research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSK is a primary research partner. HLP funds research including the RETgistry (led by Dr. Alexander Drilon) and characterization of RET mutations (led by Dr. Marc Ladanyi). MSK is also a partner in the national RET Research Coordination Center.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

GO2 Lung Cancer is a lung cancer patient advocacy organization. HLP collaborates with GO2 on patient education, registry participation (GO2 lung cancer registry), and awareness campaigns.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

A coalition focused on advancing biomarker testing in cancer care. HLP collaborates with the Biomarker Collaborative to promote the importance of biomarker testing for RET-positive lung cancer patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HLP partnered with 23andMe to launch the Lung Cancer Genetics Study, a patient registry initiative to advance RET-positive lung cancer research by collecting genetic and health information from participants.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1ROS1ders
TypeEmerging player
Description

Patient-driven nonprofit focused on ROS1-positive lung cancer. Operates the same narrow-driver-mutation model as HLP, with research funding, patient registry, and community support for a small molecularly defined NSCLC subset.

TypeBroad incumbent
Description

The largest US lung health nonprofit with a broad mandate (all lung diseases, advocacy, research, education). As a broad incumbent, it competes for the same donor dollars and has the resources to launch dedicated RET-positive programming if it chooses.

TypeBroad incumbent
Description

Funds lung cancer research across all subtypes and supports patient education. Operates a similar grant-funding and patient education model, making it a functional comparable for HLP's research funding mission.

TypeDirect peer
Description

Major lung cancer patient advocacy organization operating the lung cancer registry that HLP directs patients to. Both organizations focus on biomarker-driven patient education, clinical trial matching, and survivor support.

TypeBroad incumbent
Description

Founded by a lung cancer survivor, now part of GO2 — provides research funding and patient services across lung cancer subtypes. Comparable disease-specific nonprofit model applied to the broader lung cancer space.

TypeOthers
Description

Global professional society for thoracic oncology that HLP engages with through conference participation (WCLC). A scientific/medical community peer that plays a complementary role in advancing RET-positive research.

TypeBroad incumbent
Description

Major US cancer research nonprofit with a focus on immunotherapy. HLP funds T-cell immunotherapy research (e.g., Dr. Alexandre Reuben at MD Anderson), so the organizations share a research portfolio and donor audience.

TypeEmerging player
Description

Patient-driven nonprofit focused on EGFR-mutant lung cancer, a similarly small genomic subset. Closest model analog to HLP — small team, niche driver mutation, research funding, community building — making it a useful comparable for HLP's trajectory.

TypeDirect peer
Description

The largest US lung cancer-focused nonprofit, funding research, education, and patient support across all lung cancer subtypes. HLP is a listed collaborating partner; both organizations serve the same patient community and overlap heavily in research funding and patient education.

10RET Positive Group
TypeDirect peer
Description

Patient advocacy group specifically focused on RET-positive cancers (broader than HLP's lung-only focus). HLP is a listed collaborating partner; both serve the RET-positive patient community with education and peer support.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Happy Lungs Project

Patient Advocacy & Cancer Research Non-Profithappylungsproject.org

Happy Lungs Project firmographics

Firmographics
Name
Happy Lungs Project
Legal name
Happy Lungs Project
Website
https://happylungsproject.org
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Happy Lungs Project industry classification

Industry
Product category
Patient Advocacy & Cancer Research Non-Profit
NAICS
Voluntary Health Organizations (813212), Grantmaking and Giving Services (8132), Religious, Grantmaking, Civic, Professional, and Similar Organizations (813)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Lung cancer advocacy
  • Cancer research funding
  • Patient education resources
  • Clinical trial matching
  • Patient registry programs

Where Happy Lungs Project is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Happy Lungs Project business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Programs (research grants and patient services), Personnel, Operations, Marketing or Sales

Revenue model

  1. General Contributions (Donations): The primary revenue source is donations and general contributions from individuals, families, and supporters. Operating revenue for 2025 was $307,543 (all general contributions, no grants). For 2024, revenue was $554,878; 2023 was $362,802; 2022 was $922,265 (including $50,000 in grants); 2021 was $216,750.
  2. Research Grant Funding Facilitation: The organization facilitates additional research funding by working with cancer research institutions to assist them in securing grant funding for RET-positive research. Since inception in 2021, HLP has awarded more than $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Happy Lungs Project product offering

Product offering

Core offering

Happy Lungs Project is a 501(c)(3) nonprofit patient advocacy organization that funds and facilitates scientific research into RET-positive lung cancer, operates patient registries (RETgistry, Lung Cancer Genetics Study), and provides patient education, clinical trial matching, and community resources for RET-positive lung cancer patients, caregivers, and the broader scientific community. Since 2021 it has awarded over $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.

Product overview

The Happy Lungs Project is a nonprofit organization operating as a patient advocacy and research funding platform rather than a commercial product company. The organization offers a unified suite of patient-focused services including: a RET research funding program (having awarded over $1 million since 2021), a clinical trial matching service, patient registry enrollment support (connecting to RETgistry, GO2, and 23andMe), comprehensive patient education resources, a Video Q&A Series featuring expert scientific advisors, a newsletter program, patient Stories of Hope testimonials, an Expert Q&A service, NCCN guidelines information, and biomarker testing guidance. These services work together to advance RET-positive lung cancer research and empower patients through education and access to clinical trials and registries.

Differentiator

Problem solved

Functional benefit

Products and services

  • RET Research Funding Program
  • Clinical Trial Matching Service
  • Patient Registry Enrollment Program
  • Video Q&A Series
  • RET Newsletter Program
  • Stories of Hope Program
  • Expert Q&A Service

Quantifiable outcome

  • $1 million+ awarded in RET-positive cancer research grants since 2021
  • +3 more outcomes

Companies that use Happy Lungs Project

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Happy Lungs Project technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Happy Lungs Project partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Eli Lilly and CompanycoreStrategic or Co-development PartnerLilly is the manufacturer of selpercatinib (Retevmo), one of the two FDA-approved RET inhibitors. Happy Lungs Project collaborates with Lilly on clinical trial awareness, patient education about RET inhibitors, and research updates. Lilly pharmaceutical logo appears in the collaborating organizations section of the HLP website.
  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson is a primary research partner. HLP funds research at MD Anderson including work led by Dr. John Heymach (Chair of Thoracic/Head and Neck Medical Oncology) on RET inhibitor resistance and novel therapies, and Dr. Alexandre Reuben on T-cell immunotherapy approaches. MD Anderson serves as a lead institution in the national RET Research Coordination Center.
  • LUNGevity FoundationcoreStrategic or Co-development PartnerLUNGevity is a leading lung cancer nonprofit. The two organizations collaborate on patient education, research advocacy, and community support for the RET-positive lung cancer community.
  • Cancer Prevention Research Institute of Texas (CPRIT)coreStrategic or Co-development PartnerCPRIT is a state-funded cancer research institute in Texas. HLP collaborates with CPRIT-funded researchers and institutions working on RET-positive lung cancer research.
  • UT Southwestern Medical CentercoreStrategic or Co-development PartnerUT Southwestern is a research partner where HLP-funded research is conducted, including work by Ralf Kittler on characterizing RET fusions and resistance mechanisms. UT Southwestern is also a partner in the national RET Research Coordination Center.
  • Massachusetts General Hospital (MGH)coreStrategic or Co-development PartnerMGH is a primary research partner. HLP funds research at MGH including the RETgistry global registry (led by Dr. Jessica Lin), novel immunotherapeutic approaches (led by Dr. Justin Gainor), and work on resistance mechanisms. MGH is a core research institution for RET-positive lung cancer research.
  • Memorial Sloan Kettering Cancer Center (MSK)coreStrategic or Co-development PartnerMSK is a primary research partner. HLP funds research including the RETgistry (led by Dr. Alexander Drilon) and characterization of RET mutations (led by Dr. Marc Ladanyi). MSK is also a partner in the national RET Research Coordination Center.
  • GO2 Lung CancercoreStrategic or Co-development PartnerGO2 Lung Cancer is a lung cancer patient advocacy organization. HLP collaborates with GO2 on patient education, registry participation (GO2 lung cancer registry), and awareness campaigns.
  • Biomarker CollaborativeminorStrategic or Co-development PartnerA coalition focused on advancing biomarker testing in cancer care. HLP collaborates with the Biomarker Collaborative to promote the importance of biomarker testing for RET-positive lung cancer patients.
  • 23andMecoreStrategic or Co-development PartnerHLP partnered with 23andMe to launch the Lung Cancer Genetics Study, a patient registry initiative to advance RET-positive lung cancer research by collecting genetic and health information from participants.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Happy Lungs Project competitors and assessment

Company assessment

Emerging players

  • ROS1ders: Patient-driven nonprofit focused on ROS1-positive lung cancer. Operates the same narrow-driver-mutation model as HLP, with research funding, patient registry, and community support for a small molecularly defined NSCLC subset.
  • EGFR Resisters: Patient-driven nonprofit focused on EGFR-mutant lung cancer, a similarly small genomic subset. Closest model analog to HLP — small team, niche driver mutation, research funding, community building — making it a useful comparable for HLP's trajectory.

Broad incumbents

  • American Lung Association: The largest US lung health nonprofit with a broad mandate (all lung diseases, advocacy, research, education). As a broad incumbent, it competes for the same donor dollars and has the resources to launch dedicated RET-positive programming if it chooses.
  • Lung Cancer Research Foundation: Funds lung cancer research across all subtypes and supports patient education. Operates a similar grant-funding and patient education model, making it a functional comparable for HLP's research funding mission.
  • Bonnie J. Addario Lung Cancer Foundation (ALCF / GO2): Founded by a lung cancer survivor, now part of GO2 — provides research funding and patient services across lung cancer subtypes. Comparable disease-specific nonprofit model applied to the broader lung cancer space.
  • Cancer Research Institute: Major US cancer research nonprofit with a focus on immunotherapy. HLP funds T-cell immunotherapy research (e.g., Dr. Alexandre Reuben at MD Anderson), so the organizations share a research portfolio and donor audience.

Direct peers

  • GO2 for Lung Cancer: Major lung cancer patient advocacy organization operating the lung cancer registry that HLP directs patients to. Both organizations focus on biomarker-driven patient education, clinical trial matching, and survivor support.
  • LUNGevity Foundation: The largest US lung cancer-focused nonprofit, funding research, education, and patient support across all lung cancer subtypes. HLP is a listed collaborating partner; both organizations serve the same patient community and overlap heavily in research funding and patient education.
  • RET Positive Group: Patient advocacy group specifically focused on RET-positive cancers (broader than HLP's lung-only focus). HLP is a listed collaborating partner; both serve the RET-positive patient community with education and peer support.

Others

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Happy Lungs Project social profiles

Digital presence

Happy Lungs Project compliance and trust

Trust signal

Compliance2 records

Happy Lungs Project financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Happy Lungs Project leadership team

Management profile

Number of profiles

Profiles5 records

Happy Lungs Project funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Happy Lungs Project M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Happy Lungs Project

What does Happy Lungs Project do?

Happy Lungs Project is a 501(c)(3) nonprofit patient advocacy organization that funds and facilitates scientific research into RET-positive lung cancer, operates patient registries (RETgistry, Lung Cancer Genetics Study), and provides patient education, clinical trial matching, and community resources for RET-positive lung cancer patients, caregivers, and the broader scientific community. Since 2021 it has awarded over $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.

Is Happy Lungs Project a public or private company?

Happy Lungs Project is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Happy Lungs Project founded?

Happy Lungs Project was founded in 2021. It employs 1 to 10 people.

Where is Happy Lungs Project based?

Happy Lungs Project is headquartered in Austin, United States, in the North America region.

How does Happy Lungs Project make money?

Two revenue lines are on record. General Contributions (Donations) is the primary driver. The others are research Grant Funding Facilitation.

Who are Happy Lungs Project's main competitors?

Emerging players on record are ROS1ders and EGFR Resisters. Broad incumbents are American Lung Association, Lung Cancer Research Foundation, Bonnie J. Addario Lung Cancer Foundation (ALCF / GO2) and Cancer Research Institute. Direct peers are GO2 for Lung Cancer, LUNGevity Foundation and RET Positive Group. International Association for the Study of Lung Cancer (IASLC) is listed as an others.

Does Happy Lungs Project have an API?

No public API is recorded for Happy Lungs Project.

What industry is Happy Lungs Project in?

Happy Lungs Project's product category is Patient Advocacy & Cancer Research Non-Profit. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies. Its NAICS code is 813212 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales